Has infliximab influenced the course and prognosis of acute severe ulcerative colitis?

Angelo Viscido,1 Claudio Papi,2 Giovanni Latella,1 Giuseppe Frieri11Department of Life, Health and Environmental Sciences, University of L’Aquila, L’Aquila, Italy; 2IBD Unit, S. Filippo Neri Hospital, Rome, ItalyAbstract: Ulcerative colitis (UC) still has no definitive cure since...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Viscido A, Papi C, Latella G, Frieri G
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	ulcerative colitis acute severe ulcerative colitis mortality colectomy biologic therapy infliximab. Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/64313f3d14334b27a8806408eaa0e70f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:64313f3d14334b27a8806408eaa0e70f
record_format	dspace
spelling	oai:doaj.org-article:64313f3d14334b27a8806408eaa0e70f2021-12-02T03:22:01ZHas infliximab influenced the course and prognosis of acute severe ulcerative colitis?1177-5491https://doaj.org/article/64313f3d14334b27a8806408eaa0e70f2019-04-01T00:00:00Zhttps://www.dovepress.com/has-infliximab-influenced-the-course-and-prognosis-of-acute-severe-ulc-peer-reviewed-article-BTThttps://doaj.org/toc/1177-5491Angelo Viscido,1 Claudio Papi,2 Giovanni Latella,1 Giuseppe Frieri11Department of Life, Health and Environmental Sciences, University of L’Aquila, L’Aquila, Italy; 2IBD Unit, S. Filippo Neri Hospital, Rome, ItalyAbstract: Ulcerative colitis (UC) still has no definitive cure since its etiology remains unclear. In recent years, considerable progress has been made with regard to our knowledge of the pathogenesis of UC. Advances in biotechnology have led to the development of biologic therapies which selectively target single key mediators or receptors involved in the pathogenesis of the disease – ie, tumor necrosis factor (TNF)-α, integrin, interleukins 12/23. Biologic therapies caused a revolution in the treatment of UC, providing specific options for patients refractory to conventional treatment. In recent years, antibodies anti-TNFα and anti-integrin have shown efficacy in improving the course and prognosis of ambulatory patients with moderate-to-severe UC. Nevertheless, whether biologics have brought so many benefits also for hospitalized patients with acute severe UC is still debated. Acute severe UC is a potentially life-threatening condition that affects up to 25% of patients during the course of their disease. It requires hospital admission due to the risk of complications and death, and it can necessitate urgent colectomy. Major adverse outcomes of acute severe UC are mortality and colectomy. The aim of this systematic review of the literature was to analyze the impact of biologics, in particular infliximab, on the course and prognosis of acute severe UC. Mortality and colectomy rates were considered as outcome measures.Keywords: ulcerative colitis, acute severe ulcerative colitis, mortality, colectomy, biologic therapy, infliximabViscido APapi CLatella GFrieri GDove Medical Pressarticleulcerative colitisacute severe ulcerative colitismortalitycolectomybiologic therapyinfliximab.Medicine (General)R5-920ENBiologics: Targets & Therapy, Vol Volume 13, Pp 23-31 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	ulcerative colitis acute severe ulcerative colitis mortality colectomy biologic therapy infliximab. Medicine (General) R5-920
spellingShingle	ulcerative colitis acute severe ulcerative colitis mortality colectomy biologic therapy infliximab. Medicine (General) R5-920 Viscido A Papi C Latella G Frieri G Has infliximab influenced the course and prognosis of acute severe ulcerative colitis?
description	Angelo Viscido,1 Claudio Papi,2 Giovanni Latella,1 Giuseppe Frieri11Department of Life, Health and Environmental Sciences, University of L’Aquila, L’Aquila, Italy; 2IBD Unit, S. Filippo Neri Hospital, Rome, ItalyAbstract: Ulcerative colitis (UC) still has no definitive cure since its etiology remains unclear. In recent years, considerable progress has been made with regard to our knowledge of the pathogenesis of UC. Advances in biotechnology have led to the development of biologic therapies which selectively target single key mediators or receptors involved in the pathogenesis of the disease – ie, tumor necrosis factor (TNF)-α, integrin, interleukins 12/23. Biologic therapies caused a revolution in the treatment of UC, providing specific options for patients refractory to conventional treatment. In recent years, antibodies anti-TNFα and anti-integrin have shown efficacy in improving the course and prognosis of ambulatory patients with moderate-to-severe UC. Nevertheless, whether biologics have brought so many benefits also for hospitalized patients with acute severe UC is still debated. Acute severe UC is a potentially life-threatening condition that affects up to 25% of patients during the course of their disease. It requires hospital admission due to the risk of complications and death, and it can necessitate urgent colectomy. Major adverse outcomes of acute severe UC are mortality and colectomy. The aim of this systematic review of the literature was to analyze the impact of biologics, in particular infliximab, on the course and prognosis of acute severe UC. Mortality and colectomy rates were considered as outcome measures.Keywords: ulcerative colitis, acute severe ulcerative colitis, mortality, colectomy, biologic therapy, infliximab
format	article
author	Viscido A Papi C Latella G Frieri G
author_facet	Viscido A Papi C Latella G Frieri G
author_sort	Viscido A
title	Has infliximab influenced the course and prognosis of acute severe ulcerative colitis?
title_short	Has infliximab influenced the course and prognosis of acute severe ulcerative colitis?
title_full	Has infliximab influenced the course and prognosis of acute severe ulcerative colitis?
title_fullStr	Has infliximab influenced the course and prognosis of acute severe ulcerative colitis?
title_full_unstemmed	Has infliximab influenced the course and prognosis of acute severe ulcerative colitis?
title_sort	has infliximab influenced the course and prognosis of acute severe ulcerative colitis?
publisher	Dove Medical Press
publishDate	2019
url	https://doaj.org/article/64313f3d14334b27a8806408eaa0e70f
work_keys_str_mv	AT viscidoa hasinfliximabinfluencedthecourseandprognosisofacutesevereulcerativecolitis AT papic hasinfliximabinfluencedthecourseandprognosisofacutesevereulcerativecolitis AT latellag hasinfliximabinfluencedthecourseandprognosisofacutesevereulcerativecolitis AT frierig hasinfliximabinfluencedthecourseandprognosisofacutesevereulcerativecolitis
_version_	1718401795999399936

Has infliximab influenced the course and prognosis of acute severe ulcerative colitis?

Ejemplares similares